ghk-cu glow blend Peptide (70mg) | + BPC-157 + TB-500 GLOW Blend 70mg | Purity

The supporting evidence is overwhelmingly Khavinson-group animal and in-vitro work , much of it published in Russian-language journals with limited independent replication [11]

View Dr Snieguole Geiges profile References PubChem

the invention also relates to novel uses and methods of treatments using the aforementioned salts and/or compositions, in particular, with respect to the treatment of disturbances connected with either nitric oxide (NO) formation or impaired NO-system functions, in particular, hypertension, angina, impotence, circulatory and septic shock, stroke, inflammation, respiratory distress syndrome, adhesion and aggregation of platelets and leukocytes, endothelial dysfunction, gastrointestinal lesions, peristalsis disturbances, diabetes, pancreatitis, hypotension and Parkinson's disease

Long-term human safety has not been formally established